Mark Cuban Cost Plus Drug company joins forces with Coherus available to patients

TEXAS, USA – Mark Cuban Cost Plus Drug Company, PBC (“Cost Plus Drugs” or “Mark Cuban Cost Plus Drug Company”) and Coherus BioSciences, Inc., (“Coherus”, Nasdaq: CHRS), announced plans to offer Mark Cuban Cost Plus Drug Company customers YUSIMRY (adalimumab-aqvh), a biosimilar of HUMIRA® (adalimumab injection), in July 2023. “Humira…Read More